Plug Lands Three Electrolyzer Deals for European Green Hydrogen Projects in Hard to Decarbonize Industries
Plug will deliver 5MW containerized electrolyzer modules for first-ever use of industrial-scale green hydrogen in glass manufacturing, aluminum recycling, and steel manufacturing processes
LATHAM, N.Y., May 22, 2023 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a leading provider of turnkey hydrogen solutions for the global green hydrogen economy, landed three five megawatt (MW) electrolyzer projects with Ardagh Glass Limmared AB, Hydro Havrand, and the APEX Group for the first-ever use of industrial-scale green hydrogen in glass manufacturing, aluminum recycling, and steel manufacturing processes. Plug is the only company offering 5MW containerized PEM electrolyzers today. The standardized turnkey system, with a production capacity of more than two tons per day, reduces site construction costs and implementation complexity.
Green Glass Manufacturing:
Located east of Gothenburg, Sweden, Ardagh Glass Limmared AB is the only glass packaging producer in the Nordics and a supplier to Sweden’s most popular spirits company. Dedicated to sustainable packaging solutions, Ardagh will produce 2.1 metric tons per day (TPD) of green hydrogen by the end of the year, replacing a portion of the natural gas used today while reducing overall carbon emissions at the plant. Ardagh will use hydroelectric power to generate hydrogen from Plug’s electrolyzer.
Aluminum Recycling:
Hydro Havrand, a new unit of aluminum giant Norsk Hydro ASA, is on a mission to decarbonize heavy industry with green hydrogen. To build a close-loop circular economy for its aluminum recycling plant in Hoyanger, Norway, Hydro will employ a 5MW Plug electrolyzer module by June 2024. The electrolyzer will displace natural gas used in the plant’s burner with 2.1 metric TPD of green hydrogen. Norsk Hydro, the mother company, has deep expertise in electrolysis dating back to the 1950s.
Green Steel Manufacturing:
In Bremen, Germany, Plug and its trusted partnerAPEX Group, an integrator with strong project execution expertise, will demonstrate for the first time the feasibility of producing green steel through the decarbonization of ArcelorMittal’s local blast furnaces. Plug will deliver two 5MW electrolyzer modules with a capacity to produce 4.2 metric TPD of green hydrogen to SWB, the city’s public utility company, by the end of this year. The long-term goal is full decarbonization of the steel industry in northern Germany and the rest of Europe.
By 2030, the European Union plans to produce 10 million metric tons of green hydrogen per year to decarbonize European industries and the mobility sector. The deployment of Plug’s electrolyzers will contribute to this decarbonization roadmap.
“Plug is breaking new ground with this series of industry firsts that validate our vision to scale the green hydrogen economy,” said Plug CEO Andy Marsh. “We were bold enough to design and build the industry’s first 5MW electrolyzer module, and customers are now clambering for its holistic, compact, easy-to-install features.”
In April of 2023, Plug announced record production of its PEM electrolyzer stacks in Q1 2023, manufacturing 122MW stacks and shipping nearly 1,000 stacks totaling 5.7 MW for specialty applications. For more information about Plug’s electrolyzer product line, visithttps://www.plugpower.com/learn-more-about-plugs-electrolyzer-products/.
About Plug
Plug is building an end-to-end green hydrogen ecosystem, from production, storage and delivery to energy generation, to help its customers meet their business goals and decarbonize the economy. In creating the first commercially viable market for hydrogen fuel cell technology, the company has deployed more than 60,000 fuel cell systems and over 185 fueling stations, more than anyone else in the world, and is the largest buyer of liquid hydrogen. With plans to build and operate a green hydrogen highway across North America and Europe, Plug is building a state-of-the-art Gigafactory to produce electrolyzers and fuel cells and multiple green hydrogen production plants that will yield 500 tons of liquid green hydrogen daily by 2025. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple environments, including material handling, e-mobility, power generation, and industrial applications. For more information, visit www.plugpower.com.
Plug Safe Harbor Statement
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. (“PLUG”), including but not limited to statements about: Ardagh Glass Limmared AB’s electrolyzer producing 2.1 TPD of green hydrogen by the end of 2023, generated from hydroelectric power, to replace a portion of the natural gas used in Ardagh’s burner, reducing overall carbon emissions at the plant; Hydro Havrand’s 5 MW Plug electrolyzer module running by June 2024, displacing natural gas used in the plant’s burner with 2.1 metric TPD of green hydrogen; APEX Group demonstrating, for the first time, the feasibility of producing green steel through the decarbonization of ArcelorMittal’s local blast furnaces. Plug’s plan to deliver two 5 MW electrolyzer modules with a capacity to produce 4.2 metric TPD of green hydrogen to SWB, the city of Bremen’s public utility company, by the end of 2023 and the long-term goal of full decarbonization of the steel industry in northern Germany and the rest of Europe. The deployment of Plug’s electrolyzers contributing to the European Union’s decarbonization roadmap for 2030. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of PLUG in general, see PLUG’s public filings with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of PLUG’s Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made as of the date hereof, and PLUG undertakes no obligation to update such statements as a result of new information.
MEDIA CONTACT
Caitlin Coffee
Allison+Partners
plugPR@allisonpr.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are